SMPD4 regulates mitotic nuclear envelope dynamics and its loss causes microcephaly and diabetes

Daphne J. Smits,1 Rachel Schot,1 Nathalie Krusy,2 Katja Wiegmann,3 Olaf Utermöhlen,3 Monique T. Mulder,4 Sandra den Hoedt,4 Grace Yoon,5 Ashish R. Deshwar,5 Christina Kresge,6 Beth Pletcher,6 Maura van Mook,1 Marta Serio Ferreira,1 Raymond A. Poot,7 Johan A. Slotman,8 Gert-Jan Kremers,8 Abeer Ahmad,9 Buthaina Albash,10 Laila Bastaki,10 Dana Marafi,10,11,12 Jordy Dekker,1 Tjakko J. van Ham,1 Laurent Nguyen2 and Grazia M. S. Mancini1

Biallelic loss-of-function variants in SMPD4 cause a rare and severe neurodevelopmental disorder with progressive congenital microcephaly and early death. SMPD4 encodes a sphingomyelinase that hydrolyses sphingomyelin into ceramide at neutral pH and can thereby affect membrane lipid homeostasis. SMPD4 localizes to the membranes of the endoplasmic reticulum and nuclear envelope and interacts with nuclear pore complexes (NPC). We refine the clinical phenotype of loss-of-function SMPD4 variants by describing five individuals from three unrelated families with longitudinal data due to prolonged survival. All individuals surviving beyond infancy developed insulin-dependent diabetes, besides presenting with a severe neurodevelopmental disorder and microcephaly, making diabetes one of the most frequent age-dependent non-cerebral abnormalities. We studied the function of SMPD4 at the cellular and organ levels. Knock-down of SMPD4 in human neural stem cells causes reduced proliferation rates and prolonged mitosis. Moreover, SMPD4 depletion results in abnormal nuclear envelope breakdown and reassembly during mitosis and decreased post-mitotic NPC insertion. Fibroblasts from affected individuals show deficient SMPD4-specific neutral sphingomyelinase activity, without changing (sub)cellular lipidome fractions, which suggests a local function of SMPD4 on the nuclear envelope. In embryonic mouse brain, knockdown of Smpd4 impairs cortical progenitor proliferation and induces premature differentiation by altering the balance between neurogenic and proliferative progenitor cell divisions.

We hypothesize that, in individuals with SMPD4-related disease, nuclear envelope bending, which is needed to insert NPCs in the nuclear envelope, is impaired in the absence of SMPD4 and interferes with cerebral corticogenesis and survival of pancreatic beta cells.

1 Department of Clinical Genetics, ErasmusMC University Medical Center Rotterdam, Rotterdam 3015GD, The Netherlands
2 GIGA-Stem Cells/Neurosciences, University of Liège, CHU Sart Tilman, B-4000 Liège, Belgium
3 Institute for Medical Microbiology, Immunology, and Hygiene, University Hospital Cologne, Center for Molecular Medicine Cologne, University of Cologne, Cologne 50935, Germany
4 Department of Internal Medicine, ErasmusMC University Medical Center Rotterdam, Rotterdam, The Netherlands
5 Division of Clinical and Metabolic Genetics, Department of Paediatrics, University of Toronto, The Hospital for Sick Children, Toronto, Canada
6 Department of Genetics, Rutgers New Jersey Medical School, Newark, NJ, USA

Received September 07, 2022. Revised December 20, 2022. Accepted January 23, 2023. Advance access publication February 3, 2023
© The Author(s) 2023. Published by Oxford University Press on behalf of the Guarantors of Brain. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
Introduction

Microcephaly is a rare anomaly defined as a head circumference below −2.5 SD corrected for age and sex, and reflects reduced brain growth during development. Most children born microcephalic (congenital or primary microcephaly) present with a stable disease course, often characterized by (near) normal motor development, mild/moderate intellectual disability and speech disorder. However, another subset of children born with primary microcephaly suffers from a severe disease course with progressive reduction of head circumference, epilepsy, severe developmental delay and early demise. Genetic factors play a major role in the pathogenesis of congenital microcephaly. These factors usually decrease the factors underlying the progressive disease course are less well-characterized and have been related to abnormal endoplasmic reticulum (ER) stress response and autophagy.

SMPD4 encodes the enzyme neutral sphingomyelinase-3 and localizes to membranes of the ER and outer nuclear envelope (NE). Neutral sphingomyelinases (SMPD2–5) influence membrane lipid homeostasis by converting sphingomyelin into ceramide and phosphorylcholine. Biallelic variants in SMPD4 have recently been associated with a severe neurodevelopmental syndrome characterized by congenital and progressive microcephaly, epilepsy, congenital arthrogryposis and early demise. Moreover, a few subjects (2/19) also suffered from insulin-dependent diabetes in the first cohort describing SMPD4 loss-of-function (LoF) variants. The association between insulin-dependent diabetes and microcephaly was previously observed in rare recessive microcephalies related to ER stress and apoptosis. Loss of SMPD4 has been shown to affect ER membrane structure by causing dilatation of rough ER cisternae and increased autophagy in patient-derived cells. However, the effect of SMPD4 loss on the membrane dynamics of the NE and their contribution to human disease is unknown.

The NE is a specialized membrane that consists of two lipid bilayers, the inner and outer nuclear membranes, that separate the nucleus from the cytoplasm. The outer membrane directly derives and holds structural similarities to the rough ER. At sites where the inner and outer nuclear membranes fuse, nuclear pore complexes (NPCs) are embedded in the membrane. NPCs are multiprotein complexes that serve the selective transport of molecules between the nuclear and cytoplasmic compartment. In higher eukaryotes the NE membrane is entirely disassembled and reassembled during each cell division. During the membrane reassembly, new NPCs are stepwise inserted into the membrane. The formation of a novel NE with properly inserted nuclear pores not only requires strict regulation of membrane expansion, but also needs the induction of membrane curvature. Several membrane-shaping proteins and phosphorylation events are known to regulate membrane dynamics during NE disassembly, reassembly and NPC insertion. However, the regulation of lipid composition and its impact during these processes is still poorly understood.

The observation of SMPD4 variants in the pathogenesis of microcephaly offers an unprecedented opportunity to study the function of neutral sphingomyelinases in NE and cell cycle dynamics during brain development. In this study, we expand the knowledge of SMPD4-related disease by describing five previously unreported affected individuals with prolonged survival, who had microcephaly and developed insulin-dependent diabetes in childhood. We used both in vitro and in vivo systems to gain insight into the function of SMPD4 in NE dynamics and in the developing brain cortex.

Materials and methods

Study approval

The study was approved by the local Institutional Review Board (Erasmus MC Rotterdam, protocol METC-2012387).

Consenting of human subjects

Written informed consent for participation in the study and scientific publication of analysed data and clinical photographs was obtained. GeneMatcher was used to recruit additional previously unreported subjects with biallelic SMPD4 variants and connect with clinicians of previously published subjects for longitudinal and follow-up phenotypic data when available.

Mice

All mice were handled according to the ethical guidelines of the Belgian Ministry of Agriculture in agreement with European Community Laboratory Animal Care and Use Regulations (86/609/ CEE, Journal Officiel des Communautés Européennes, L358, 18 December 1986). All mice were wild-type (WT) SWISS pregnant females purchased from Janvier Labs and were housed under standard conditions (animals were bred in-house and maintained with ad libitum access to food and constant temperature (19–22°C) and humidity (40%–50%) under a 7 a.m. to 7 p.m. light/dark cycle).
Exome sequencing methods

Exome sequencing (ES) was performed on DNA isolated from blood of probands and family members, as previously described. ES data are deposited in each medical institute, with respect for the privacy of the families. Details of sequencing and analysis pipelines are described for each family in the Supplementary material.

Statistics

All statistical tests were performed with Prism GraphPad 9 Software. All datasets were tested for outliers and normality. All error bars represent the SEM. P-values <0.05 were considered significant. Details about the statistical tests are available in the figure legends.

Data availability

ES data are deposited at each medical institute referring the individuals, in respect to the privacy of the families.

Results

Undescribed cases with variants in SMPD4 present with microcephaly and insulin-dependent diabetes

Biallelic variants in SMPD4 have been described in 25 affected children from 16 unrelated families over the past few years.4–7 We expand the phenotype related to SMPD4 variants by describing the first three adult subjects and presenting two new paediatric cases with additional clinical features. In addition, we provide longitudinal follow-up data on a previously published case. Extensive clinical reports and detailed descriptions of the identified variants are available in the Supplementary material and Supplementary Table 3. Lastly, we provide a summary of the clinical features observed in all published cases with biallelic SMPD4 variants (Table 1).

Family 1

The individuals from this consanguineous family are the first reported adults with SMPD4 variants (Fig 1A). The family consists of three affected daughters, aged 45, 43 and 41 years. At the last examination, all individuals present with microcephaly (~−4 to −5 SD), short stature and moderate to severe intellectual disability (IQ range: 20–40). All three sisters were reported with ataxia and tremors. Joint contractures were not noted. Interestingly, all sisters developed insulin-dependent diabetes during their teenage years. Two of them also presented with retinal dystrophy and hearing loss. They started walking at 2 years of age. As this family consulted the genetics clinic for the first time at adult age, extensive information about their perinatal/paediatric features is unavailable. Exome sequencing revealed a homozygous missense variant in SMPD4 in all three affected daughters [NM_01751.4(SMPD4):c.2431C>T p.(Arg811Cys)]. This variant has a very low minor allele frequency in gnomAD (0.0022%) and is absent in homozygous state in gnomAD controls. This variant was predicted to be deleterious by SIFT, probably damaging by PolyPhen-2 and benign by MutationTaster. Both parents were heterozygous carriers of the variant and their healthy son is wild-type.

Family 2

The second family includes one affected child born with congenital bilateral talipes equinovarus. He was reported to be borderline microcephalic (~−2 SD), hypotonic and delayed in all domains of development at 1 year of age. At the age of 5 years, he developed additional contractures of both knees and hips. This boy was diagnosed with insulin-dependent diabetes at the age of 15 years. A brain MRI was completed at age 11 years, which revealed diffuse simplification of the gyral pattern, thickening of the cerebral cortex, a thin corpus callosum and decreased volume of the cerebellar vermis (Fig. 1B–D). Trio exome sequencing revealed a homozygous single basepair deletion in SMPD4. The variant is denoted as c.940delT and results in a frameshift and creation of a premature stop codon [NM_01751.4(SMPD4):c.940delT p.(Ser314Profs*60)]. Both parents were confirmed to be heterozygous carriers of the variant. To study the effect of this variant on SMPD4 expression, RNA was isolated from primary fibroblasts of the affected proband. Quantitative reverse transcriptase-PCR (RT-PCR) indicates that the expression of SMPD4 is 80% reduced in patient-derived cells, confirming the pathogenicity of this variant (Supplementary Fig. 1A).

Family 3

After the original report (Family 8 in Magini et al.), a new sibling was born in this family and follow-up was recorded. Currently, this family consists of three affected children born from consanguineous parents. One of these siblings (Family 3 Subject VI-2; Fig. 1E) was previously described in Magini et al.4 During infancy this subject presented with respiratory failure, severe microcephaly (~−6 SD), arthrogryposis, generalized seizures, vocal cord paralysis, feeding intolerance, hypertonisa, intermittent sinus bradycardia and persistent foramen ovale. In this individual, a homozygous nonsense variant was identified [NM_01751.4(SMPD4): c.370G>T; p.(Glu124*)]. Follow-up at 5 years of age revealed several additional features, including insulin-dependent diabetes, focal segmental glomerulosclerosis and retinal dystrophy. The same variant was identified in the newborn sibling in this family (Family 3 Subject VI-3; Fig. 1F and G). This subject presented with a similar disease course including persistent respiratory failure, generalized seizures, severe progressive microcephaly (~−6 SD), distal arthrogryposis and severe global developmental delay. Like his brother, this sibling developed type 1 diabetes at 4 years of age. In addition, he showed long QT syndrome, chorea and dyskinesia of the tongue. A third sibling in this family (Family 3 Subject VI-1), who presented with similar features, died in utero in the seventh month of the pregnancy.

Summary of the SMPD4-related phenotype

Following on from our cohort published in 2019, additional individuals harbouring variants in SMPD4 have been described.4–7 Most of these individuals presented with microcephaly, arthrogryposis and severe neurodevelopmental delay. Table 1 provides a summary of all features observed in all described SMPD4 cases (n = 30), including the novel cases presented in this study. This summary shows that intrauterine growth retardation (IUGR), microcephaly at birth, arthrogryposis and severe developmental delay are the most prevalent features. The microcephaly had a progressive character in almost all subjects for whom follow-up data were available (85%). On the other hand, few cases were reported with normal occipital frontal circumference (OFC) measurements at birth, but developed microcephaly later on. Another frequently observed manifestation in this cohort is neonatal respiratory distress (73%). This feature was mainly observed in severely affected individuals and is the most frequently reported cause of death in infancy.
Besides the core phenotypic features, additional features were observed in the new cases. First, we observed a remarkable increase in individuals that present with insulin-dependent diabetes (27%). This observation was frequently made in individuals who survived beyond infancy. The age of diabetes onset was between 3 and 15 years of age, and if reported these children were negative for anti-insulin, anti-glutamic acid decarboxylase (anti-GAD) and anti-islet antigen 2 (anti-IA2) antibodies. Moreover, individuals from three families presented with visual defects reported as retinal dysrophy, macular dystrophy, retinal pigment epithelial stippling and nystagmus. Lastly, several cardiac defects were described in addition to the previously reported hypertrophic cardiomyopathy. These defects included persistent ductus arteriosus, persistent foramen ovale and long QT syndrome, but each has been sporadically reported. From this observation, the only consistent and frequent feature, besides the neurological abnormalities, seems to be insulin-dependent diabetes, with childhood onset.

### SMPD4 pathogenic variants

In total, 19 unique intragenic variants in SMPD4 are described, of which five are missense variants, four are nonsense variants, five are splice site variants predicted to result in a frameshift, four are confirmed frameshift variants and one is a genomic deletion including exons 18–20 of SMPD4. In addition, two bigger genomic deletions including SMPD4 were described. The missense variants are spread over the entire protein structure (Fig. 1H). All variants, including the missense, are absent or have a very low frequency in control cohorts and are predicted to have deleterious effects on protein functioning. An overview of all described pathogenic variants

<table>
<thead>
<tr>
<th>Disease manifestation</th>
<th>Number of individuals with biallelic SMPD4 variants (n = 30)</th>
<th>% of all assessed individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Growth parameters and survival</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IUGR</td>
<td>15/24</td>
<td>62.5</td>
</tr>
<tr>
<td>Congenital microcephaly</td>
<td>19/26</td>
<td>73.1</td>
</tr>
<tr>
<td>Length &lt; −2.5 SD at birth</td>
<td>6/12</td>
<td>50.0</td>
</tr>
<tr>
<td>Prematurity</td>
<td>10/22</td>
<td>45.5</td>
</tr>
<tr>
<td>Death in infancy (&lt;1 year of age)</td>
<td>9/27</td>
<td>33.3</td>
</tr>
<tr>
<td>Neonatal respiratory distress</td>
<td>16/22</td>
<td>72.7</td>
</tr>
<tr>
<td><strong>Neurological abnormalities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Progressive microcephaly</td>
<td>11/13</td>
<td>85.0</td>
</tr>
<tr>
<td>Seizures</td>
<td>14/25</td>
<td>56.0</td>
</tr>
<tr>
<td>Persistent respiratory distress</td>
<td>12/25</td>
<td>48.0</td>
</tr>
<tr>
<td>Congenital arthrogryposis</td>
<td>23/30</td>
<td>76.6</td>
</tr>
<tr>
<td>Developmental delay</td>
<td>15/15</td>
<td>100.0</td>
</tr>
<tr>
<td>Facial dysmorphisms</td>
<td>20/20</td>
<td>100.0</td>
</tr>
<tr>
<td><strong>Brain MRI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Simplified gyration</td>
<td>17/23</td>
<td>73.9</td>
</tr>
<tr>
<td>Thin corpus callosum</td>
<td>13/24</td>
<td>54.2</td>
</tr>
<tr>
<td>Hypomyelination</td>
<td>11/23</td>
<td>47.8</td>
</tr>
<tr>
<td>Cerebellar hypoplasia</td>
<td>11/24</td>
<td>45.8</td>
</tr>
<tr>
<td>Brainstem hypoplasia</td>
<td>5/24</td>
<td>20.8</td>
</tr>
<tr>
<td>Thickening of the cortex</td>
<td>1/24</td>
<td>4.2</td>
</tr>
<tr>
<td><strong>Non-neurological systemic abnormalities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Congenital heart defect</td>
<td>11/25</td>
<td>44.0</td>
</tr>
<tr>
<td>Atrial septum defect</td>
<td>4/25</td>
<td>16.0</td>
</tr>
<tr>
<td>Persistent ductus arteriosus</td>
<td>5/25</td>
<td>20.0</td>
</tr>
<tr>
<td>Long QT</td>
<td>1/25</td>
<td>4.0</td>
</tr>
<tr>
<td>Dilated cardiomyopathy</td>
<td>1/25</td>
<td>4.0</td>
</tr>
<tr>
<td>Ventricular septum defect</td>
<td>2/25</td>
<td>8.0</td>
</tr>
<tr>
<td>Transposition of great arteries</td>
<td>1/25</td>
<td>4.0</td>
</tr>
<tr>
<td>Insulin-dependent diabetes</td>
<td>7/26 (age of onset between 3 and 14 years)</td>
<td>27.0</td>
</tr>
<tr>
<td>Ocular anomalies:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Retinopathy</td>
<td>3/17</td>
<td>17.6</td>
</tr>
<tr>
<td>Macular dystrophy</td>
<td>1/17</td>
<td>5.9</td>
</tr>
<tr>
<td>Faint corneal opacity</td>
<td>1/17</td>
<td>5.9</td>
</tr>
<tr>
<td>Renal disease:</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Focal segmental glomerulosclerosis</td>
<td>1/11</td>
<td>9.1</td>
</tr>
<tr>
<td>Mild pyelectasis</td>
<td>1/11</td>
<td>9.1</td>
</tr>
<tr>
<td>Multicystic dysplastic kidney</td>
<td>1/11</td>
<td>9.1</td>
</tr>
<tr>
<td>Muscular tone</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hypotonic</td>
<td>5/19</td>
<td>26.3</td>
</tr>
<tr>
<td>Hypertonic</td>
<td>12/19</td>
<td>63.2</td>
</tr>
<tr>
<td>Normotonic</td>
<td>2/19</td>
<td>10.5</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Disease manifestation</th>
<th>Number of individuals with biallelic SMPD4 variantsa</th>
<th>% of all assessed individuals</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>IUGR</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Congenital microcephaly</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Length &lt; −2.5 SD at birth</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Prematurity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Death in infancy (&lt;1 year of age)</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neonatal respiratory distress</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Neurological abnormalities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Progressive microcephaly</strong>b</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Seizures</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Persistent respiratory distress</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Congenital arthrogryposis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Developmental delay</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Facial dysmorphisms</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Brain MRI</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Simplified gyration</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Thin corpus callosum</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypomyelination</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Cerebellar hypoplasia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Brainstem hypoplasia</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Thickening of the cortex</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Non-neurological systemic abnormalities</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Congenital heart defect</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Atrial septum defect</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Persistent ductus arteriosus</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Long QT</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Dilated cardiomyopathy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ventricular septum defect</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Transposition of great arteries</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Insulin-dependent diabetes</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ocular anomalies:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Retinopathy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Macular dystrophy</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Faint corneal opacity</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Renal disease:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Focal segmental glomerulosclerosis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Mild pyelectasis</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Multicystic dysplastic kidney</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Muscular tone</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypotonic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Hypertonic</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Normotonic</strong></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

IUGR = intrauterine growth retardation.

aThe number of individuals with SMPD4 variants for which detailed clinical information was available.
bDefined as >0.5 SD occipital frontal circumference (OFC) decline after birth.
Figure 1 Clinical phenotype and SMPD4 variants. (A) Pedigrees of the three described families. Affected individuals are indicated with filled symbols. (B–D) Brain MRI of the affected Subject II-3 Family 2, at 11 years of age. T1-weighted images show simplified gyration, thickening of the cortex (B and C), thin corpus callosum (D) and reduced volume of the cerebellar vermis (D). (E–G) Facial features of affected Subjects 2 (E) and 3 (F and G) from Family 3. (H) Schematic overview of the SMPD4 protein structure, the known protein domains and all identified intragenic pathogenic variants. New variants described in this manuscript are depicted below the protein structure. Previously described variants are depicted above the protein structure. (I) Subcellular localization of the SMPD4 proteins containing missense variants Pro192Leu, Leu231Pro, Pro446Leu in HEK293T cells. Samples were costained with the ER marker anti-calnexin (CNX, green) and anti-myc (red) and DAPI (blue). Scale bars = 5 μm. (J) Co-localization of SMPD4-mutant proteins with CNX was determined by calculating Pearson’s correlation coefficient (Kruskal-Wallis test, n = >20 cells per group, n = 3 experiments, P < 0.0001).
in SMPD4 and their frequency is provided in Supplementary Table 4.
To assess the pathogenic mechanisms of SMPD4 missense variants
we introduced the previously reported variants p.(Leu446Pro),
p.(Pro231Leu) and p.(Pro192Leu) into a human Myc-tagged SMPD4
plasmid.4,5 These plasmids were transiently transfected in
HEK293T cells and the proteins were followed by co-localization
studies with markers of the ER and NPC by confocal microscopy.
All mutants showed localization to the ER and the NE/NPC, similar
as the wild-type protein (Fig. 1I and Supplementary Fig. 1B).
However, the mutant p.(Pro446Leu) (Pearson’s correlation coefficient = 0.53)
showed less co-localization with the ER membrane
marker calnexin, as compared to wild-type SMPD4 (Pearson’s correlation coefficient = 0.75) and the mutants p.(Pro192Leu)
(Pearson’s correlation coefficient = 0.67) and p.(Pro231Leu)
(Pearson’s correlation coefficient = 0.75; Fig. 1I). In addition, overexpression of p.(Pro446Leu) seemed to affect the calnexin distribution
(Fig. 1I). These data show that the variants do not induce major alterations in the localization patterns, although one shows reduced
localization to the ER.

SMPD4 loss affects cell division and apoptosis in
human neural stem cells

Congenital microcephaly is often caused by a decrease number in
neuronal progenitor that followed their impaired proliferation
rates, e.g. DNA synthesis and mitotic defects, or their increased
cell death.1,2 We have previously demonstrated that primary fibro-
blasts from individuals expressing LoF variants in SMPD4 show de-
fects in cell division and are more susceptible to undergo apoptosis.3

In order to gain insight in the effects of SMPD4 depletion on
neural cell lineages, cell proliferation and apoptosis were investi-
gated in human neural stem cells (hNSCs). These pluripotent stem cells can be used as surrogate of precursors of neuronal and
glial progenitors, and hence are a good model for a proliferation de-
fect. First, the proliferating capacities of hNSCs were assessed by
measuring 5-ethynyl-2’-deoxyuridine (EdU) incorporation after
knockdown of SMPD4 with siRNAs (siSMPD4; Fig. 2A and
Supplementary Fig. 1C). Lipofection of siSMPD4 led to a significant
decrease in Edu-positive cells compared to treatment with siCTRL
(Fig. 2B; siCTRL: 55.5%, siSMPD4: 34.2%). Afterwards, susceptibility
of siSMPD4-treated hNSCs to undergo apoptosis was investigated
by detecting apoptotic DNA fragments after stress induction with
0.1 mM hydrogen peroxide treatment. hNSCs expressing siSMPD4
showed a significant increase in cells with apoptotic foci (46%) as
compared to controls (30.8%; Supplementary Fig. 1D and E). These
data confirm that the increased susceptibility to apoptosis observed
in native fibroblasts from affected individuals results from
SMPD4 depletion and demonstrates that SMPD4 is essential to
maintain proliferating capacities and cell survival in neuronal
lineages.

Cell cycle duration in SMPD4-depleted cells

The impact of SMPD4 depletion on the cell cycle was further inves-
tigated by real-time live imaging of fibroblasts from individuals
with LoF SMPD4 variants and hNSCs treated with siSMPD4.
 Fibroblasts with LoF variants in SMPD4 showed a prolonged mitosis
without morphological abnormalities during cell division as com-
pared to controls. The observed average mitotic duration in
SMPD4-depleted fibroblasts was 1.22 times longer as compared to
controls (Fig. 2C–E and Supplementary Videos 1 and 2; controls:
58 min; SMPD4 LoF variant: 71 min). The effect of SMPD4 depletion
on mitotic duration was confirmed in hNSCs, as the average mitotic
duration increased 1.47 times after siSMPD4 treatment (Fig. 2F
and Supplementary Videos 3 and 4; siCTRL: 38 min; siSMPD4: 56 min).
The contribution of morphological abnormalities to the increased
mitotic duration was evaluated in more detail. We evaluated biop-
lar spindle formation, chromosome (mis)segregation and spindle
length in fibroblast and mitotic ER localization upon siSMPD4 in
HEK293T cells but did not observe any overt differences during
these processes (Supplementary Fig. 2A–C).

SMPD4 depletion disrupts nSMase3 activity without changing (sub)cellular lipidome fractions

Although SMPD4 (also named nSMase-3) has been shown to have neutral sphingomyelinase activity, there are no reports about its enzymatic activity in native human cells.21 We investigated sphingosine-phosphodiesterase activity of cultured fibroblasts of affected individuals using 14C-labelled sphingomyelin at neutral pH, according to Quinter and Sandhoff.16-17 SMPD4-specific sphingo-
myelinase activity was elicited by treatment with tumor necrosis factor α (TNFa), in order to distinguish it from other neutral sphin-
gomyelinases, as previously described.23 Cell homogenates derived from unrelated affected subjects with complete SMPD4 LoF variants (Families 1 and 2 from Magini et al.4) already showed decreased sphingomyelinase activity and no induction of its activity upon
TNFa treatment. TNFa treatment of SMPD4 LoF cells did not pro-
mote induction of enzymatic activity while the control cells did show a clear response (Fig. 2G). This demonstrates that the human
mutations impair the neutral sphingomyelinase activity in cul-
tured fibroblasts and confirm that SMPD4 is a TNFa-dependent neutral sphingomyelinase.

In fibroblasts and HEK293T cells, SMPD4 localizes to the NE mem-
brane and interacts with several NPC components. Therefore, we
evaluated the effect of SMPD4 depletion on the lipid composition of
the nuclear membrane. Nuclear-enriched fractions were isolated
from fibroblasts of individuals with SMPD4 LoF variants and control
fibroblasts for lipidomic analysis. The purity of the nuclear fractions
was confirmed with immunoblots probing the nuclear maker
lamina-associated polypeptide-2 (LAP2; Supplementary Fig. 3A).
Several sphingolipid subtypes were quantified, including sphingo-
myelin, ceramide and sphingosine 1 phosphate (S1P). Fibroblasts
derived from individuals with LoF variants in SMPD4 did not show any
alteration in sphingomyelin or ceramide levels when compared to
several control fibroblast lines (Fig. 2H and I). S1P levels were below
the limit of detection in all samples and therefore could not be deter-
mined accurately. This demonstrates that SMPD4 is probably not
the major neutral sphingomyelinase in cultured cells controlling the
global sphingolipid/ceramide pool of nuclear membranes, but
may have a specific local effect on the NPC membrane. Therefore,
we focused on aspects of NPC morphology and NE dynamics.

SMPD4 regulates nuclear envelope dynamics and nuclear pore complex insertion

The morphology of the NE was examined to evaluate the effect
of SMPD4 deficiency on the membrane structure. The NE morphology
was first studied on fixed fibroblasts with the NE marker LAP2.
Alterations in NE morphology were observed in fibroblasts derived
from three unrelated affected individuals (Supplementary Fig. 3B).
These cell lines showed an increased number of invaginations
from the inner nuclear membrane into the nucleoplasm (21%),
Figure 2. SMPD4 depletion disturbs cell cycle progression and reduces nSMase activity.

(A) The Click-IT EdU proliferation assay was performed on hNSCs 48 h after siSMPD4 or siCTRL transfections. Cells that did incorporate EdU during incubation are shown in lighter colour (red), all nuclei were counterstained with DAPI. Scale bars = 10 µm. (B) Quantification of the percentage of proliferating hNSCs. The number of EdU+ cells was calculated as a percentage of all DAPI+ nuclei (unpaired t-test with Welch’s correction, two-tailed, n = >5 fields per slide, n = 2 experiments, P < 0.0001). (C and D) Time-lapse brightfield microscopic imaging of human control fibroblasts (C) and fibroblasts harbouring LoF SMPD4 variants (D, Family 1 from Magini et al.).

(E) Quantification of the mitotic duration observed in C and D (n = 2 cell lines with SMPD4 LoF variants: Families 1 and 2 from Magini et al., n = 3 control cell lines, unpaired t-test, two-tailed, P = 0.0014). (F) Quantification of the time-lapse brightfield microscopic imaging of human NSCs treated for 48 h with siSMPD4 or siCTRL siRNAs (n = 3 experiments, unpaired t-test with Welch’s correction, two-tailed, P < 0.0001). (G) nSMase enzymatic activity assay. Fibroblasts were treated with TNFα to induce nSMase-3 activity after which the production of radioactive phosphorylcholine produced from 14C-SM was quantified (n = 2–3 experiments, n = 2 cell lines with SMPD4 LoF variants: Families 1 and 2 from Magini et al., n = 2 control cell lines, one-way ANOVA with Sídák post hoc test, **P = 0.0004, ****P < 0.0001). (H and I) Tandem mass spectrometry (MS/MS) profiling sphingomyelin (SM, H) and ceramide (Cer, I) subtypes in nuclear fractions of control fibroblasts and fibroblasts harbouring LoF SMPD4 variants. Cer and SM subtypes were distinguished based on their fatty acyl chain length (n = 1 experiment, n = 2 control cell lines, n = 2 cell lines with SMPD4 LoF variants: Families 1 and 2 from Magini et al.).
compared to control cell lines (9.9%; Supplementary Fig. 3B–D). As these invaginations can be a normal feature during mitotic NE breakdown and reassembly, live NE dynamics were studied by live-imaging of overexpressed lamin B receptor (LBR)-green fluorescent protein (GFP) marker, in HEK293T cells after SMPD4 knockdown.

Before the onset of mitosis, NE-associated dynein generates pulling forces on microtubules that emanate from the centrosomes. These pulling forces lead to the formation of NE invaginations around centrosomes in prophase and facilitate NE disassembly. In siCTRL-treated cells, the formation of these NE invaginations was almost immediately followed by complete disassembly of the NE and progression into metaphase (Supplementary Video 5). Instead, siSMPD4-treated cells showed a significant delay between the formation of these invaginations, membrane disassembly and metaphase in independent biological replicates (siCTRL: 33.6 min, siSMPD4: 60.0 min). The time span from metaphase until the onset of NE rebuilding was similar in both groups. Following chromatin separation, siSMPD4 cells did start reassembly of the novel NE in late anaphase, similar to siCTRL-treated cells. However, in the absence of SMPD4, the subsequent closure and expansion of the NE resulted in polyleob membrane structures and a significant delay in the formation of a closed NE (Fig. 3A and B; siCTRL: 40.2 min, siSMPD4: 70.1 min). During interphase, nuclei of siSMPD4-treated cells did not show increased infoldings, which suggests that the invaginations seen with LAP2 antibodies on fixed sections are related to NE membrane remodelling events during mitosis. These results correlate SMPD4’s neutral sphingomyelinase activity specifically to the NE assembly during mitosis.

During NE reassembly, large numbers of NPCs have to be inserted in the new NE. To assess the effect of altered NE membrane structure on NPC insertion, we counted NPC numbers. Three-dimensional structured illumination microscopy (3D SIM) was used to identify NPCs labelled with the mAb414 antibody, which recognizes phenylalanine-glycine (FG) repeat-containing NPCs. Initially, NPC numbers were counted in all cell-cycle phases. Fibroblasts derived from unrelated individuals with SMPD4 variants showed a significantly decreased number of NPCs per nuclear surface area (Fig. 3C and Supplementary Fig. 3E; Controls: 4.87 pore/μm²; SMPD4 LoF variants: 3.99 pore/μm²). As NPC assembly can occur in the post-mitotic phase and during interphase, we used the post-mitotic marker CD1 and late G2 marker CyclinB to discriminate between these two processes. Fibroblasts derived from unrelated patients with SMPD4 variants contained fewer nuclear pores per nuclear surface area in both post-mitotic conditions (Fig. 3D) and during interphase (Fig. 3E; Controls: 4.28 pore/μm²; SMPD4 LoF variants: 3.6 pore/μm²). These data show that SMPD4 disruption not only delays post-mitotic NE membrane assembly, but also alters post-mitotic NPC assembly. To obtain additional evidence for a role of SMPD4 in post-mitotic NPC biogenesis, we used RNAi to knockdown SMPD4 in hNSCs and counted NPCs in CDT1-positive cells. In SMPD4-depleted hNSCs we observed a decrease of NPCs per nuclear surface area (Fig. 3F; siCTRL: 4.4 pore/μm², siSMPD4: 3.6 pore/μm²). Altogether, these data showed that depletion of SMPD4 interferes with the NE dynamics during mitosis, which is compatible with impaired post-mitotic insertion of NPCs.

SMPD4-GFP localizes to pericentriolar regions during mitosis

SMPD4 activity does not alter global sphingolipid pool, but regulates NE assembly. We thus hypothesize that its function might relate to its subcellular localization. To test this we followed SMPD4 localization during mitosis with live confocal imaging. Human SMPD4 was subcloned into a pEGFP-C1 vector. As expected, SMPD4-GFP-C1 localized to the NE and ER in interphase after transient overexpression in HEK293T cells (Supplementary Fig. 4A). In addition, co-precipitation of SMPD4-GFP with NUP153 and NUP62 was observed, confirming close association with NPCs (Supplementary Fig. 4B and C). At the onset of mitosis (early prophase) SMPD4-GFP accumulated at one site near the nuclear rim (Supplementary Video 6). This strong signal was subsequently split into two signals, which both localized to sites of mitotic NE invagination. These findings suggested the enrichment of SMPD4 to regions surrounding the centrosomes during the onset of mitosis.

To confirm this observation, we performed co-stainings of SMPD4-GFP with the centrosomal marker γ-tubulin (Fig. 4A). We observed a localization of SMPD4 to pericentriolar regions during all mitotic stages. However, this co-localization was most pronounced during (early) prophase.

The formation of a new NE around chromatin starts in late anaphase. As major defects were observed in NE reassembly and NPC insertion upon SMPD4 depletion, we assessed the localization of SMPD4-GFP to chromatin surrounding during these processes. We observed localization of SMPD4 to the vicinity of chromatin after cell division (Fig. 4A and B). Co-stainings with the nuclear pore marker 414 showed that SMPD4 punctae in these phases localize together with NPC marker.

SMPD4 loss decreases cortical progenitor proliferation and alters their fate

We next tested whether SMPD4 is also required for the proliferation of the apical progenitors that reside in the ventricular zone (VZ) and that generate projection neurons during embryogenesis. We thus depleted Smpd4 in apical progenitors from embryonic Day 14.5 (E14.5) mice by in utero electroporation of two validated small hairpin (sh)RNAs targeting Smpd4, referred to as Smpd4_A and Smpd4_B (Supplementary Fig. 5A and B). This was followed 2 days later by a single injection of Edu (50 mg/kg) in pregnant dams 1 h before sacrifice of the embryos to label cortical cells undergoing S-phase. We determined the proliferation rate (cell undergoing mitosis) by quantifying the percentage of Edu+ cells in apical progenitors (SOX2+ that were targeted by electroporation (GFP*) / (SOX2+ + GFP* + Edu*) / (SOX2+ + GFP*) × 100%). Apical progenitors transfected with the shSmpd4 vectors showed a reduction in proliferation rate as compared to those targeted with the shCtrl (Fig. 5A and B; shCtrl: 43%; shSmpd4_A: 23%; shSmpd4_B 28%). We next tested whether the reduction of proliferation rate observed upon depletion of SMPD4 was correlated with an increase of cell-cycle exit. For this purpose, embryos were electroporated at E14.5, then injected with Edu (50 mg/kg) at E15.5 and finally sacrificed 20 h later (E16.5) for analysis. The fraction of progenitors that did exit the cell cycle (Ki67−) upon proliferation in the last 20 h was quantified (Ki67− + GFP* + Edu*) / (Edu* + GFP*) × 100%; Fig. 5C and Supplementary Fig. 5C) and showed that the downregulation of SMPD4 in apical progenitors led to an increase in cell cycle exit (shSmpd4_A/B: 50%), as compared to shCtrl-targeted apical progenitors (shCtrl 41%).

To assess whether the promotion of cell-cycle exit upon depletion of Smpd4 resulted in an increased neuronal output, we quantified the proportion of newborn expression of the neuronal marker βIIIITubulin [βIIIITub+ + GFP* + Edu*] / (EdU* + GFP*) × 100%. ShSmpd4-targeted cells showed an increase in
Figure 3 SMPD4 regulates NE membrane structure and NPC insertion. (A) Live HEK293T-cells expressing exogenous lamin B receptor–GFP were imaged during mitosis 72 h after siRNA transfection with siSMPD4 or siCTRL. The periods of NE reassembly were defined as: the first frame in which NE invaginations were visible until the first frame of metaphase; metaphase until the first frame of visible NE reassembly; the first frame of visible NE reassembly until a closed rounded NE without the presence of irregularities. The lower panels show outlines of the developing NE structure. (B) Quantification of A, showing the duration of each mitotic phase in minutes (one-way ANOVA with Sídák post hoc test, n = 3 experiments, n = > 50 cells per group, **P = 0.0022, ***P = 0.0005). (C) 3D SIM super resolution images showing FG-repeat containing nuclear pores (anti-mab414) in control fibroblast. (D and E) Fibroblasts were counterstained with cell-cycle markers CDT1 (D, post-mitotic phase) or cyclinB1 (E, G2-phase). The number of mab414+ nuclear pores per µm was counted in CDT1/CyclinB1-positive cells with 3D SIM high-resolution microscopy [n = 2–3 experiments, unpaired t-test, two-tailed, P = <0.0001 (D), P = 0.019 (E), scale bars = 1 µm]. (F) The number of nuclear pores (anti-mab414) was quantified in hNSCs treated for 48 h with siSMPD4 or siCTRL siRNAs. hNSCs were costained with the CDT1 antibody to visualize post-mitotic cells (n = 2 experiments, unpaired t-test with Welch’s correction, two-tailed, P = <0.0001).
Figure 4 SMPD4-GFP localizes to pericentriolar regions during mitosis. (A) Fluorescent confocal images showing SMPD4-GFP-C1 (first column, green) localization in mitotic HEK293T cells during different stages of cell division. Antibodies against γ-tubulin (second column, red) were used to visualize centrosomes. Nuclei were counterstained with DAPI (third column, blue). (B) Antibodies against mab414 (second column, red) were used to visualize co-localization of SMPD4-GFP (first column, green) with nuclear pores during NE/NPC reassembly in telophase and anaphase (n = 2 experiments, n = >5 cells per experiment, scale bars = 1 µm).
Figure 5 SMPD4 depletion in embryonic mice cortex affects apical progenitor proliferation and fate. (A and B) Immunostainings on cryosections of E16.5 mouse cortices, 48 h after electroporation, for GFP (green), EdU (top row, red) and SOX2 (magenta) to determine the percentage of proliferating apical progenitors (scale bars = 10 µm, n = 5–6 brains, one-way ANOVA with Sidák post hoc test, **P = 0.0018, ***P = 0.0001). (C) Quantification of triple immunostainings for GFP, Ki67 and EDU on shRNA electroporated cortices, performed to calculate the percentage of cells exiting the cell cycle at E16.5, 2 days after electroporation (n = 5–6 brains, one-way ANOVA with Sidák post hoc test, **P = 0.0028 shSmpd4_A versus ctrl, **P = 0.0055 shSmpd4_B versus ctrl). (D and E) Triple immunostainings for GFP, βIII-Tubulin (top row, magenta) and EdU on shRNA electroporated cortices used to quantify the production of neuronal cells at E16.5, 2 days after electroporation (scale bars = 20 µm, n = 5 brains, one-way ANOVA with Sidák post hoc test, \( P < 0.0001 \)). (F and G) Distribution of shRNA-electroporated cells at E16.5, 48 h after electroporation (scale bars = 50 µm, n = 5 brains, one-way ANOVA with Sidák post hoc test; VZ/SVZ: Ctrl versus shSmpd4_A2 P = 0.0004, Ctrl versus shSmpd4_B1 P = 0.0020; CP Ctrl versus shSmpd4_A2 P = 0.0036). Subdivisions of the cortical wall were made by nucleus density (DAPI) and are indicated with dashed lines: CP = cortical plate; IZ = intermediate zone; SVZ/VZ = subventricular zone/ventricular zone.
SMPD4 in NE dynamics and corticogenesis

While we focused on NE membrane dynamics, SMPD4 is also known to localize to the ER and we have previously shown that its absence leads to signs of ER stress, apoptosis and increased autophagy in skin fibroblasts. To our knowledge, insulin-dependent diabetes has not been observed in individuals with variants in genes regulating NE homeostasis, while insulin-resistant type 2 diabetes has been described in laminopathy-related LMNB2 mutations, causing abnormally lobed interphase nuclei and other laminopathies like Dunnigan syndrome. In addition, the combination of microcephaly and diabetes has been described several times in children with variants in ER stress-related genes. We hypothesize that the insulin-dependent diabetes could be related to the function of SMPD4 in NE dynamics as well as to its function in the ER by causing susceptibility to apoptosis. We therefore recommend control of glucose metabolism in the diagnostic work-up and regular controls in the follow-up of subjects with SMPD4-related disorder.

A decrease in neuronal progenitor numbers during embryonic brain development is known to result in microcephaly. This decrease can be caused by dysregulation of the balance between symmetric and asymmetric divisions of apical progenitors. Symmetric divisions result in two apical progenitors, while asymmetric divisions result in one apical progenitor and one intermediate progenitor or a projection neuron. Recent studies show that prolonged mitosis of neuronal progenitors alters neuronal cell fate by altering the balance between symmetric and asymmetric cell divisions and increasing apoptosis. We report that loss of SMPD4 prolongs mitosis in hNSCs and human SMPD4-deficient fibroblasts. We also show that in mouse embryos, loss of SMPD4 resulted in an altered balance of neurogenic and proliferative progenitor cell divisions. Although we have not measured mitotic duration directly in embryonic mouse brain, the prolonged mitotic duration observed in SMPD4-depleted hNSCs provides a good explanation for this observation. Prolonged mitosis might not only interfere with the balance in progenitor cell divisions, but also impact the survival of neuronal progenitors. While SMPD4-depleted cells were more susceptible to undergo apoptosis upon hydrogen peroxide treatment, we did not observe increased cell death in cells with NE remodelling defects. Recent studies have shown that, in the pathogenesis of microcephaly, depletion of apical progenitors is not always associated with apoptosis.

The absence of SMPD4 interfered with normal NE disassembly and reassembly during mitosis. Moreover, it led to decreased insertion of new NPCs. While the importance of NE homeostasis and NPC biogenesis in the development of microcephaly has previously been suggested, the SMPD4-related disorder is the first human disease linked to the regulation of NE/NPC dynamics at the lipid level. Variants in NE protein ANKLE2 are related to microcephaly with simplified gyration, corpus callosum agenesis, cerebellar hypoplasia and skin pigmentation defects. ANKLE2 regulates NE reassembly during mitotic exit and its depletion results in destabilization of the inner NE, with polylobed NE structures after mitosis, reminiscent of the SMPD4-related phenotype shown here. Variants in LMNB1, encoding for inner nuclear membrane lamin B1, disrupt NE integrity and nuclear lamina disassembly and result in severe congenital microcephaly with short stature, variable intellectual disability and epilepsy. Also, variants in different NPC proteins...
Other membrane bending factors, such as RTN4, YOP1 and RET1, have been shown to be important for mitotic NE remodelling and NPC insertion. While loss of SMPD4 has been shown to result in ER stress signs in vitro, we did not observe upregulation of ER stress markers in the apical progenitors of embryonic mice. However, our observations took place in a limited time window and follow-up studies in transgenic animals could provide the answer to this question.

We show for the first time that fibroblasts with complete LoF variants in SMPD4 have a deficiency of SMPD4-specific TNF-stimulated nSmase activity. This observation is crucial to demonstrate that the protein coded by SMPD4 has in itself both an enzymatic activity and a lipid-regulating function. Interestingly, its loss does not alter the global lipidome, either in the total cell homogenate or in the nuclear subcellular fraction. These findings raise the possibility that SMPD4 is required for the regulation of local or transient changes in membrane lipid composition. Because ceramide production induces membrane curvature, it is possible that SMPD4 contributes to the formation of membrane curvature during NE reassembly and NPC insertion. The new NE initially forms from mitotic ER stacks that are recruited to chromatin. Afterwards, membrane-remodelling events occur to build a bilayer membrane with new NPCs inserted. Other membrane bending factors, such as RTN4, YOP1 and RET1, have been shown to be important for mitotic NE remodelling and NPC insertion. While further studies are needed to gain insight into the direct effect of SMPD4 on membrane remodelling, we hypothesize that the ceramides produced by SMPD4 contribute to NE reassembly and NPC insertion via the induction of membrane curvature.

NE breakdown is controlled by the phosphorylation of NE and NPC proteins. It is generally assumed that these phosphorylation events disrupt the interactions between NE or NPC components at the onset of mitosis. Large studies mapping mitotic phosphorylation sites found SMPD4 to be one of the proteins that becomes phosphorylated during mitosis. This phosphorylation step may disrupt the interactions with other NE components, but could also regulate the enzymatic activity of SMPD4 during mitosis. While the role of NE lipid metabolism during NE breakdown is poorly explored, it is suggested that membrane remodelling factors and lipid-metabolizing enzymes are recruited to the centrosome during the onset of the breakdown. Interestingly, we observed relocalization of SMPD4 to the regions surrounding the centrosomes in early prophase. During this cell-cycle phase, the centrosome is tethered to the NE to regulate breakpoints and is thought to serve as a regional hub to direct remodelling of the NE.

Altogether, we show that loss of neutral sphingomyelinase-3 (SMPD4) not only results in a severe developmental disorder with microcephaly, but also causes age-related insulin-dependent diabetes. Our results show the importance of this sphingomyelinase in maintenance of the neuronal progenitor pool and regulation of cell-cycle exit during embryonic cortical development. At the cellular level, our results provide new mechanistic insights into the role of sphingolipid metabolism during mitotic NE remodelling, NPC insertion and mitotic progression. Follow-up studies that investigate the biochemical properties of SMPD4-depleted membranes will provide information about the direct effects of sphingolipid metabolism on membrane properties and membrane dynamics. This could also provide additional insights into the role of other lipids during NE breakdown, NE reassembly and NPC insertion and their potential contribution to human disease. Our results confirm that variants in genes regulating NE homeostasis, NPC insertion and/or mitotic progression should be considered in patients with severe progressive microcephaly.

Acknowledgements

We thank the patients and their families for participation in this study. We thank Dr Maarten Fornerod and Dr Niels Galjart for fruitful discussions and their support.

Funding

G.M.S. is supported by ZonMW Top grant #91217045. D.J.S is supported by an EMBO fellowship #8857.

Competing interests

The authors report no competing interests.

Supplementary material

Supplementary material is available at Brain online.

References

9. Poulton CQ, Schot R, Kia SK, et al. Microcephaly with simplified gyration, epilepsy, and infantile diabetes linked to...


